Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update

Artelo Biosciences, Inc. (NASDAQ:ARTL) saw a large decline in short interest in the month of February. As of February 13th, there was short interest totaling 53,039 shares, a decline of 52.0% from the January 29th total of 110,410 shares. Approximately 3.0% of the shares of the company are sold short. Based on an average daily volume of 28,117 shares, the short-interest ratio is presently 1.9 days. Based on an average daily volume of 28,117 shares, the short-interest ratio is presently 1.9 days. Approximately 3.0% of the shares of the company are sold short.

Analyst Ratings Changes

ARTL has been the subject of several research reports. Maxim Group restated a “hold” rating on shares of Artelo Biosciences in a research report on Wednesday, November 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Artelo Biosciences in a research report on Monday, December 29th. One research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $24.00.

Artelo Biosciences Stock Performance

Shares of Artelo Biosciences stock opened at $1.19 on Friday. The stock has a market capitalization of $2.52 million, a P/E ratio of -0.06 and a beta of 1.13. Artelo Biosciences has a 52-week low of $1.10 and a 52-week high of $28.60. The stock’s 50-day simple moving average is $1.46 and its 200 day simple moving average is $3.40.

Artelo Biosciences Company Profile

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development of novel small-molecule therapies for pain, inflammation, ocular and cardiometabolic disorders. The company leverages a proprietary drug delivery and targeting platform designed to enhance the safety and efficacy profiles of well-characterized active pharmaceutical ingredients. Artelo’s approach is centered on repurposing and optimizing therapeutic molecules to address significant unmet medical needs, with particular emphasis on improving patient tolerability and clinical outcomes.

The company’s lead program, AB101, is an orally bioavailable ion channel modulator in development for neuropathic pain conditions including post-herpetic neuralgia.